Several other representative anti-TROP2 ADCs are in clinical trials for indications involving TNBC, non-small cell lung cancer, ovarian cancer, bladder cancer, and gastric cancer [12, 18, 29]. Here, TACSTD2 is linked to non-small cell lung carcinoma.